- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04393337
Estimating Length of Endotracheal Tube Insertion Using Gestational Age or Nasal-Tragus Length in Newborn Infants (ELEGANT)
Gestational Age Versus Nasal-tragus Length for Estimating Endotracheal Tube Insertion Depth in Newborns - A Randomised Trial
Endotracheal intubation is a life-saving intervention that few infants need after birth. Although an endotracheal tube is the most reliable way of providing positive-pressure breath, the critical factor that determines the maximal efficacy of positive-pressure ventilation is the optimal placement of the endotracheal tube tip. There are various methods available to determine the initial depth of endotracheal tube (ETT) that are based on the infant's birth weight, gestational age, anthropometric measurements, and others include vocal cord guide and suprasternal palpation methods.
The Neonatal Resuscitation Program (NRP) textbook, in its 7th edition of the textbook, recommends a gestational age chart and nasal-tragus length method for estimating endotracheal tube insertion depth during cardiopulmonary resuscitation of the neonate. The evidence to support these two methods is, however, limited. Hence, we designed this study to determine the accuracy of two methods, gestational age chart and nasal-tragus length method, recommended by the Neonatal Resuscitation Program.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Trial Objective: To determine whether estimating ETT insertion depth using gestational age chart rather than nasal-tragus length method results in more correctly positioned ETT tips.
Setting: The neonates will be recruited from multiple tertiary-level neonatal intensive care units in Saudi Arabia. A neonate can participate in more than one clinical trial, depending on the interventions being given. Parallel run trials will be discussed between the chief and local principal investigators whether or not joint recruitment is feasible to both parties.
Informed Consent: We will obtain written consent after the parents have been given a full verbal explanation and written description. We will explain to the parents in their own native language. We will use a hospital-based adult interpreter wherein required. We will obtain deferred consent (after initial verbal assent) where prior consent is not feasible as the study does not involve additional risk or investigations to the participants, and the interventions are otherwise considered as standard practice recommendations by the NRP.
Data Safety Monitoring Board: Any unexpected serious events (death, any life-threatening event, any event that will prolong the hospitalization or any event that will result in disability) will be reported to the data safety monitoring committee. The trial steering committee will receive recommendations from the data safety monitoring board if the trial requires early termination following the interim data analyses and evidence from relevant studies. The following measures were agreed to consider stopping the trial, wholly or partly (subgroups), after an interim analysis, that will be done after recruiting 200 participants.
- An absolute difference of greater than or equal to 25% in the primary outcome between the study groups.
- An absolute difference of less than 5% in the primary outcome between the study groups.
- A rate of less than 20% in the primary outcome in either of the groups.
Sample Size: Our unpublished data showed using the nasal-tragus length method results in 35% of correctly positioned ETT tips in term and preterm infants. The data is similar to the randomized and non-randomized studies that showed an accuracy between 32 and 37 percent using the nasal-tragus length method. With 90% power and two-sided 5% significance, to detect an absolute increase in optimally positioned ETT tips of 15%, we will require 454 participants. We calculated sample size using nQuery Advisor Sample Size Calculator version 8.3.0.0.
Statistical Analysis: We will analyze the data based on the intention-to-treat principle. Univariate analyses will be performed to compare baseline demographic factors between the two groups. A mean with standard deviation (normal data) or median with interquartile range (skewed data) will be obtained for continuous variables and numbers and percentages for categorical variables. Independent T-test (normal data) or Mann Whitney U test (skewed data) for continuous variables and chi-square test (or Fisher's exact test as appropriate) for categorical variables will be used for analyses between the groups. Statistical Analysis Software version 9.4 will be used for the conduct of all analyses.
Analysis of primary outcome: Adjusted risk ratios of a successful outcome will be calculated along with 95% confidence intervals. Adjusted ratios will be determined by way of multivariable logistic regression analysis, including co-variates deemed biologically to have an influence on the primary outcome (gestational age, small for gestational age, and center). Principles of best model practices will be followed (including assessment of collinearity amongst included variables) as well as the determination of the predictive ability of the model using area under the curve.
Analysis of secondary outcomes: Similar analyses as above will be performed for all secondary outcomes that are categorical variables. The risk ratios of secondary outcomes mortality, oxygen therapy at 28 days, pneumothorax, and bronchopulmonary dysplasia will be adjusted based on the following variables: gestational age, male sex, small for gestational age, maternal hypertension, chorioamnionitis, antenatal steroids, and center if the P-value is less than 0.25 on univariate analysis.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Al Bahah, Saudi Arabia
- Recruiting
- King Fahad Hospital, AlBaha University
-
Contact:
- Jameel Alghamdi
- Phone Number: 00966555770733
- Email: dr.jameelalghamdi@hotmail.com
-
Riyadh, Saudi Arabia
- Recruiting
- King Faisal Specialist Hospital & Research Centre
-
Contact:
- Abdulaziz Binmanee
- Phone Number: 00966565454292
- Email: zizmaze@hotmail.com
-
Riyadh, Saudi Arabia, 13412
- Recruiting
- King Abdullah bin Abdulaziz University Hospital
-
Contact:
- Abdul Razak, MD
- Phone Number: 3526 0118200000
- Email: aarazak@kaauh.edu.sa
-
Principal Investigator:
- Abdul Razak, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Infants (less than 28 days of life) between 23 weeks 0 days and 41 weeks 6 days gestational age
- Infants requiring oral intubation in the delivery room or in neonatal intensive care unit
Exclusion Criteria:
- Infants with major chromosomal anomalies, including trisomy 13, trisomy 18, and trisomy 21
- Infants with major anomalies, including craniofacial anomalies and facial dysmorphism that may affect the nasal-tragus length
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gestational Age Chart Method
In this method, the endotracheal tube insertion depth is obtained from the gestational age chart provided in the 7th edition textbook of neonatal resuscitation program (adapted from Kempley et al.
PubMed identifier number: 18372092)
|
The endotracheal tube insertion depth is obtained by the gestational age chart
|
Active Comparator: Nasal-Tragus Length Method
In this method, the endotracheal tube insertion depth is calculated based on the formula-the distance from nasal septum tip to ear tragus+1 cm
|
The endotracheal tube insertion depth is obtained by the nasal-tragus method formula
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of infants with optimally positioned endotracheal tube tip on the chest X-ray
Time Frame: within 4 hours of endotracheal intubation
|
Endotracheal tube tip is considered optimally positioned if the tip lies between upper border of first thoracic vertebra (T1) and the lower border of second thoracic vertebra (T2) on the chest X-ray.
While obtaining the antero-posterior view chest X-ray in supine position, the infant's head, neck and chest is placed in the midline with no tension on the endotracheal tube and neck being in neutral position (i.e.
neck neither flexed nor extended).
Just before obtaining the film, the investigator/research assistant should re-confirm that the endotracheal tube is secured in a standardize manner at the estimated depth based on the treatment arm assigned.
|
within 4 hours of endotracheal intubation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of infants with endotracheal tube tip above T1 vertebra
Time Frame: within 4 hours of endotracheal intubation
|
Presence of endotracheal tube tip above the upper border of first thoracic vertebra e of endotracheal tube tip below the lower border of second thoracic vertebra on the chest X-ray
|
within 4 hours of endotracheal intubation
|
Proportion of infants with endotracheal tube tip below T2 vertebra
Time Frame: within 4 hours of endotracheal intubation
|
Presence of endotracheal tube tip below the lower border of second thoracic vertebra on the chest X-ray
|
within 4 hours of endotracheal intubation
|
Proportion of infants with pneumothorax
Time Frame: 36 weeks of post-menstrual age
|
Presence of air in the pleural space determined by a chest X-ray
|
36 weeks of post-menstrual age
|
Proportion of infants with requiring endotracheal tube repositioning (advance or withdrawn) following chest X-ray
Time Frame: 24 hours
|
Repositioning of the endotracheal tube will be done based on attendings discretion
|
24 hours
|
Proportion of infants with oxygen therapy
Time Frame: 28 days from the birth
|
Any supplemental oxygen (>21%) on invasive or non-invasive respiratory support
|
28 days from the birth
|
Proportion of infants with bronchopulmonary dysplasia
Time Frame: 36 weeks of post-menstrual age
|
It is defined as oxygen therapy or positive pressure support (include nasal cannula <2 liter/minute and >30% oxygen, nasal cannula >2 liters/minute and any oxygen, continuous positive airway pressure and any oxygen, or invasive respiratory support and any oxygen)
|
36 weeks of post-menstrual age
|
Ventilation days
Time Frame: 36 weeks of post-menstrual age
|
Duration of invasive ventilation
|
36 weeks of post-menstrual age
|
Proportion of infants with mortality
Time Frame: 36 weeks of post-menstrual age
|
Death occurring anytime from birth until discharge
|
36 weeks of post-menstrual age
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-0148
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumothorax
-
Tabriz University of Medical SciencesAJA University of Medical SciencesUnknownPneumothorax, Spontaneous | Pneumothorax Spontaneous Primary | Pneumothorax, Recurrent | Pneumothorax Spontaneous TensionIran, Islamic Republic of
-
Peking University Third HospitalNot yet recruitingPrimary Spontaneous Pneumothorax
-
Rennes University HospitalRecruiting
-
University Hospital, Strasbourg, FranceRecruiting
-
Chinese University of Hong KongRecruitingPneumothorax, SpontaneousHong Kong
-
Dow University of Health SciencesUnknownSecondary PneumothoraxPakistan
-
Johns Hopkins UniversityRecruitingPneumothorax | Tension PneumothoraxUnited States
-
University of RochesterWithdrawn
-
Ain Shams UniversityRecruitingPrimary and Secondary Spontaneous PneumothoraxEgypt
-
Centre Hospitalier Universitaire de BesanconInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingPneumothorax Iatrogenic PostproceduralFrance, Ireland
Clinical Trials on Gestational Age Chart Method
-
International Centre for Diarrhoeal Disease Research...University of California, DavisCompletedSmall for Gestational Age at Delivery | Post-term Infant, Not Heavy-for-datesBangladesh
-
Medical University of ViennaCompletedBrain Activity | Neurodevelopmental OutcomeAustria
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnCervical Cancer | Precancerous Condition
-
Hospices Civils de LyonCompleted
-
Société des Produits Nestlé (SPN)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Completed
-
Corcept TherapeuticsCompleted
-
National Cancer Research NetworkUnknown
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed